Ipamorelin
Growth Hormone Release, Ghrelin-Receptor & Metabolic Research
SUPPORTED BY HUMAN RESEARCH
NOT ESTABLISHED
NOT APPROVED
What Is Ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide, or pentapeptide, that acts as a growth hormone secretagogue.
Unlike CJC-1295, which acts through the growth hormone-releasing hormone pathway, Ipamorelin acts primarily as an agonist of the ghrelin receptor, also known as the growth hormone secretagogue receptor. Activation of these receptors in the hypothalamus and pituitary can stimulate release of the body's own growth hormone (GH). FDA describes both Ipamorelin free base and Ipamorelin acetate as related investigational substances.
Early research attracted attention because Ipamorelin appeared relatively selective for GH release compared with some older growth hormone-releasing peptides. In animal experiments, researchers observed GH stimulation without the same increases in ACTH and cortisol seen with GHRP-2 or GHRP-6.
Important: Ipamorelin is not FDA-approved for any therapeutic indication. GH release is supported by human pharmacology research, while broader clinical outcomes such as muscle gain, fat loss, recovery, sleep, or anti-aging benefits are much less established.
Why Are Researchers Interested?
Ipamorelin is primarily interesting because researchers developed it as a relatively selective way of stimulating endogenous growth hormone release. Areas that have been investigated or proposed include:
Human pharmacology studies demonstrate that Ipamorelin can cause a measurable episode of GH release. However, the clinical significance of that hormonal response depends on what health outcome is being studied. Increasing growth hormone is a biological effect. It does not automatically establish muscle gain, fat loss, improved recovery, better sleep, or anti-aging benefits.
What The Research Suggests
Ipamorelin Can Stimulate Growth Hormone in Humans
One of the most important human studies examined Ipamorelin pharmacokinetics and growth-hormone responses in healthy male volunteers. Participants received one of five intravenous infusion levels.
Researchers found that Ipamorelin stimulated GH at every dose studied; GH peaked at approximately 0.67 hours; GH then declined toward negligible concentrations; Ipamorelin's terminal half-life was approximately 2 hours; and GH response varied considerably among individuals. The investigators concluded that Ipamorelin produced a clear, dose-related GH response in healthy volunteers.
This provides legitimate human evidence that Ipamorelin acts as a growth hormone secretagogue. It does not establish that long-term administration improves health outcomes.
Ipamorelin Was Developed for Relative GH Selectivity
A foundational 1998 study described Ipamorelin as a potent GH secretagogue. Researchers compared Ipamorelin with other growth hormone-releasing peptides in laboratory and animal experiments.
Ipamorelin stimulated GH release through a GHRP-type receptor mechanism. In the animal models studied, it did not significantly increase ACTH or cortisol at levels comparable to the increases observed with GHRP-2 and GHRP-6. This led researchers to characterize Ipamorelin as a comparatively selective growth hormone secretagogue.
But an important limitation is that much of this selectivity evidence comes from rats and swine, not long-term human clinical trials.
Ipamorelin Is a Ghrelin-Receptor Agonist
Modern understanding of Ipamorelin places it within the broader family of ghrelin-receptor agonists. Ghrelin receptors participate not only in growth-hormone regulation but also in appetite signaling, gastrointestinal function, energy balance, neuroendocrine signaling, and reward-related brain pathways.
FDA notes that Ipamorelin acts as a ghrelin-receptor agonist and that activity at these receptors outside the pituitary creates additional biological and safety considerations. So describing Ipamorelin merely as a “GH booster” oversimplifies its pharmacology.
Gastrointestinal Motility Has Been Studied
Ipamorelin has also been investigated for postoperative ileus, a temporary impairment of intestinal movement that can occur after abdominal surgery. Animal studies suggested that Ipamorelin could increase gastric and intestinal motility after surgery.
That led to a multicenter randomized, double-blind, placebo-controlled human trial involving patients undergoing bowel resection. A total of 117 patients were enrolled. Participants received intravenous Ipamorelin or placebo. The median time to tolerating a solid meal was 25.3 hours with Ipamorelin versus 32.6 hours with placebo.
However, the difference was not statistically significant at the primary endpoint. Therefore, the study did not establish Ipamorelin as an effective treatment for postoperative ileus.
Evidence At A Glance
Growth Hormone Release
Healthy-volunteer research demonstrated a measurable, dose-related episode of GH release following Ipamorelin administration.
Selectivity for GH Release
Animal and laboratory studies suggest greater GH selectivity than some older GHRPs, particularly regarding ACTH and cortisol responses.
Growth Hormone Deficiency
FDA concluded that available information did not establish clinical effectiveness for Ipamorelin-related substances in growth hormone deficiency.
Muscle Growth / Body Recomposition
A plausible GH-related mechanism exists, but adequate controlled human outcomes research is lacking.
Fat Loss / Weight Loss
Ipamorelin is not an FDA-approved obesity or weight-management medication.
Recovery / Sleep / Anti-Aging
These commonly marketed benefits go beyond the available controlled human evidence.
Safety & Limitations
The biggest limitation surrounding Ipamorelin is the small amount of human safety information, particularly for the subcutaneous injectable use commonly discussed in peptide clinics. FDA's review found that adequate nonclinical toxicity studies were limited and that clinical safety information was insufficient to establish safety for the proposed uses.
Human Adverse Events
In the postoperative-ileus clinical program involving intravenous Ipamorelin, reported adverse events included hypokalemia, insomnia, hyperglycemia, nausea, vomiting, and abdominal distention. Two deaths occurred during the clinical study, although FDA states that it was unclear whether the deaths were related to Ipamorelin.
That qualification is important. The existence of deaths during a study does not establish that Ipamorelin caused them. It does demonstrate why safety cannot be described as established.
Subcutaneous Safety Data Are Particularly Limited
This matters greatly because wellness clinics frequently discuss subcutaneous Ipamorelin. FDA specifically noted that it had not identified adequate safety information for Ipamorelin administered through certain other injectable routes, including the type of administration commonly associated with compounded peptide products.
Evidence involving IV administration therefore cannot simply be assumed to establish the safety of chronic subcutaneous administration.
Glucose Regulation
Growth hormone can influence glucose metabolism. FDA noted that there was insufficient information to determine whether Ipamorelin-related substances might share safety concerns associated with other compounds that stimulate GH release, including glucose intolerance and diabetes mellitus.
The postoperative-ileus clinical study also included reports of hyperglycemia. This does not establish that Ipamorelin causes diabetes. It means glucose metabolism remains an important unresolved safety consideration.
Immunogenicity and Product Quality
FDA has raised concerns about compounded Ipamorelin involving peptide aggregation, peptide-related impurities, API characterization, manufacturing quality, injectable-product sterility and purity, and potential immunogenicity. Ipamorelin also contains unnatural amino acids, which FDA notes adds complexity to characterization of the substance.
FDA's current compounding safety resource states that the agency lacks sufficient information to determine whether compounded Ipamorelin acetate would cause harm through certain injectable routes.
Ghrelin-Receptor Effects Extend Beyond Growth Hormone
Ipamorelin's activity is not limited to the pituitary gland. FDA notes that ghrelin receptors are distributed in several tissues and brain regions and that pharmacological activation can potentially affect systems beyond GH secretion.
This is another reason that “selective GH release” should not be interpreted as “no other biological effects.”
Regulatory Status
No. Ipamorelin is not FDA-approved for any therapeutic indication. It is not FDA-approved for growth hormone deficiency, muscle growth, fat loss, weight management, body recomposition, exercise recovery, sleep, anti-aging, longevity, postoperative ileus, or general wellness. FDA has evaluated both Ipamorelin free base and Ipamorelin acetate in connection with pharmacy compounding.
What About Compounding?
This is an especially important section for Ipamorelin. FDA evaluated Ipamorelin free base and Ipamorelin acetate for possible inclusion on the 503A Bulks List. FDA concluded that, based on physical and chemical characterization, historical use, effectiveness evidence and safety information, the available evidence weighed against inclusion of both substances.
On October 29, 2024, FDA's Pharmacy Compounding Advisory Committee voted against placing either substance on the 503A Bulks List. Advisory-committee votes are recommendations to FDA rather than FDA approvals themselves, but the result is highly relevant when describing Ipamorelin's regulatory status. For 503B outsourcing facilities, FDA currently identifies Ipamorelin acetate in Category 2 — substances that raise significant safety risks under its interim policy.
Regulatory Status: Not FDA-Approved — Ipamorelin is not FDA-approved for growth hormone deficiency, muscle growth, fat loss, recovery, anti-aging, or any other therapeutic indication. FDA has identified significant limitations in the available effectiveness and safety evidence and has raised concerns regarding compounded Ipamorelin-related products. Future regulatory status cannot be predicted.
Ipamorelin vs. CJC-1295
Both compounds can influence growth hormone, but they approach the GH axis through different receptors and biological pathways. That mechanistic difference is one reason CJC-1295 and Ipamorelin are sometimes discussed together.
Ipamorelin
Acts primarily as a ghrelin-receptor / growth hormone secretagogue receptor agonist. Its signaling can stimulate the pituitary to release growth hormone.
CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates growth hormone release through the GHRH receptor pathway.
Why the Difference Matters: Evidence demonstrating biological activity for each individual compound should not be interpreted as clinical proof that a CJC-1295/Ipamorelin combination produces greater muscle gain, fat loss, recovery, sleep improvement, or anti-aging effects. The combination requires its own clinical evidence.
Research & Publications
FDA Scientific Review — Ipamorelin Free Base & Ipamorelin Acetate
U.S. Food and Drug Administration — 2024
FDA's detailed scientific evaluation covering Ipamorelin chemistry, GH biology, proposed uses, postoperative ileus research, safety, toxicology, immunogenicity, and Section 503A compounding considerations.
View FDA Ipamorelin Scientific ReviewPharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers
Pharmaceutical Research — 1999
A human dose-escalation study evaluating Ipamorelin pharmacokinetics and growth-hormone responses in healthy male volunteers. Researchers demonstrated GH release at all studied dose levels.
View on PubMedIpamorelin — The First Selective Growth Hormone Secretagogue
European Journal of Endocrinology — 1998
Foundational laboratory and animal research describing Ipamorelin's GH-releasing activity and relative selectivity compared with GHRP-2 and GHRP-6.
View on PubMedRandomized Trial of Ipamorelin for Postoperative Ileus
Diseases of the Colon & Rectum — 2015
A multicenter, randomized, double-blind, placebo-controlled study of intravenous Ipamorelin in patients undergoing bowel resection. The primary endpoint did not demonstrate a statistically significant improvement compared with placebo.
View on PubMedIpamorelin and Muscle/Bone Biology in Rats
Growth Hormone & IGF Research — 2002
Preclinical research examining whether Ipamorelin could counter glucocorticoid-related changes in muscle and bone formation in adult rats.
View on PubMedFDA Pharmacy Compounding Advisory Committee — Ipamorelin
U.S. Food and Drug Administration — October 29, 2024
Official FDA meeting materials covering Ipamorelin free base and Ipamorelin acetate and their consideration for the Section 503A Bulks List.
View FDA Advisory Committee MaterialsFDA Pharmacy Compounding Advisory Committee — Final Meeting Minutes
U.S. Food and Drug Administration — 2024
The official meeting record documents the committee's 0–12–1 votes against inclusion of both Ipamorelin free base and Ipamorelin acetate on the 503A Bulks List.
View FDA Final Meeting RecordFDA — Potential Safety Risks With Compounded Ipamorelin
U.S. Food and Drug Administration
FDA discusses potential immunogenicity, aggregation, peptide-related impurities, unnatural amino acids, limited injectable safety information, and adverse events observed during clinical research.
View FDA Compounding Safety ResourceFDA — Section 503A Compounding Framework
U.S. Food and Drug Administration
Explains the federal requirements governing the bulk drug substances that state-licensed physicians and pharmacies may use when compounding under Section 503A.
View FDA 503A Compounding InformationIpamorelin is an investigational growth hormone secretagogue with human pharmacology evidence demonstrating that it can stimulate endogenous growth hormone release.
That biological activity should not be confused with established clinical treatment benefits. Current evidence does not establish Ipamorelin as an effective treatment for muscle growth, fat loss, weight management, athletic recovery, improved sleep, anti-aging, longevity, or general wellness.
The human research base is limited, and much of the broader benefit profile associated with Ipamorelin comes from biological reasoning, animal research, or extrapolation from the wider GH/IGF-1 system rather than adequate controlled human outcome trials.
Ipamorelin is not FDA-approved for any therapeutic indication, and FDA has identified unresolved concerns involving effectiveness, human safety, injectable administration, immunogenicity, and product characterization.
This page is provided for educational purposes only. Ipamorelin is not offered for sale, prescription, or distribution through this website.